

12-30-04

B. [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-006; A-415H)

PATENT

In re Application of: Fisher et al. )

Serial No.: 09/882,735 )

Filed: June 15, 2001 )

For: Truncated Soluble Tumor Necrosis )  
Factor Type-I and Type-II Receptors )

Before the Examiner: E. O'Hara

Group Art Unit: 1646

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

**TRANSMITTAL LETTER**

1. We are transmitting herewith the attached papers for the above-described patent application:  
Amendment under 37 C.F.R. § 1.312 and return postcard.
2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on December 29, 2004.

Respectfully submitted,  
McDonnell Boehnen Hulbert & Berghoff

Dated: December 29, 2004

By:   
Donald L. Zuhn, Ph.D.  
Reg. No. 48,710



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-006; A-415H)

PATENT

In re Application of: Fisher et al. )

Serial No.: 09/882,735 )

Before the Examiner: E. O'Hara

Filed: June 15, 2001 )

Group Art Unit: 1646

For: Truncated Soluble Tumor Necrosis )  
Factor Type-I and Type-II Receptors )

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT UNDER 37 C.F.R. § 1.312**

Applicants respectfully request that the following additional amendments be entered prior to issuance of the above-described patent application pursuant to 37 C.F.R. §1.312.

**Amendments to the Claims:** Pursuant to 37 C.F.R. § 1.121, Applicants present a complete listing of the claims, including marked up versions of all currently amended claims, at pages 2-8.

**Remarks:** Applicants' Remarks begin on page 9 of this paper.